Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Ally, Mahmood M T M ^a   Hodkinson, Bridget ^b   Meyer, Pieter W A ^a   Musenge, Eustasius ^c   Tikly, Mohammed ^b   Anderson, Ronald ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; RHEUMATOID FACTOR; SERUM AMYLOID A; STROMELYSIN; VASCULOTROPIN; AUTOANTIBODY; BIOLOGICAL MARKER; MATRILIN;

ADULT; ARTICLE; CARTILAGE DEGENERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EROSION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; SMOKING; BLOOD; METABOLISM; PATHOLOGY; RADIOGRAPHY;

ACUTE-PHASE PROTEINS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MATRILIN PROTEINS; MATRIX METALLOPROTEINASE 3; SMOKING;

EID: 84877270600     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/183653     Document Type: Article

References (40)

1. Pratt A. G., Isaacs J. D., Mattey D. L., Current concepts in the pathogenesis of early rheumatoid arthritis. Best Practice and Research: clinical Rheumatology 2009 23 1 37 48 2-s2.0-60449096601 10.1016/j.berh.2008.08.002
2. Karouzakis E., Neidhart M., Gay R. E., Gay S., Molecular and cellular basis of rheumatoid joint destruction. Immunology Letters 2006 106 1 8 13 2-s2.0-33746225592 10.1016/j.imlet.2006.04.011 (Pubitemid 44093056)
3. Kobayashi A., Naito S., Enomoto H., Shiomoi T., Kimura T., Obata K., Inoue K., Okada Y., Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Archives of Pathology and Laboratory Medicine 2007 131 4 563 570 2-s2.0-34147142891 (Pubitemid 46564428)
4. Jones G. C., Riley G. P., Buttle D. J., The role of proteases in pathologies of the synovial joint. International Journal of Biochemistry and Cell Biology 2008 40 6-7 1199 1218 2-s2.0-43049088767 10.1016/j.biocel.2008.01. 024
5. Galliera E., Banfi G., Corsi M. M., Human bone disorders: pathological role and diagnostic potential of matrix metalloproteinases. International Journal of Biochemistry and Cell Biology 2010 42 10 1590 1593 2-s2.0-77956187501 10.1016/j.biocel.2010.06.015
6. Manicone A. M., McGuire J. K., Matrix metalloproteinases as modulators of inflammation. Seminars in Cell and Developmental Biology 2008 19 1 34 41 2-s2.0-36849094431 10.1016/j.semcdb.2007.07.003 (Pubitemid 350235986)
7. Hueber A. J., Asquith D. L., McInnes I. B., Miller A. M., Embracing novel cytokines in RA-complexity grows as does opportunity! Best Practice and Research 2010 24 4 479 487 2-s2.0-77956140432 10.1016/j.berh.2010.01.004
8. Cawston T. E., Wilson A. J., Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Practice and Research 2006 20 5 983 1002 2-s2.0-33748484703 10.1016/j.berh.2006.06.007 (Pubitemid 44356460)
9. Connolly M., Mullan R. H., McCormick J., Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis and Rheumatism 2012 64 4 1035 1045
10. Chizzolini C., Brembilla N. C., Montanari E., Truchetet M. E., Fibrosis and immune dysregulation in systemic sclerosis. Autoimmunity Reviews 2011 10 5 276 281 2-s2.0-79952043928 10.1016/j.autrev.2010.09.016
11. Cunnane G., Oliver F., Beeton C., Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis and Rheumatism 2001 44 10 2263 2274 (Pubitemid 32977494)
12. Szekanecz Z., Koch A. E., Angiogenesis and its targeting in rheumatoid arthritis. Vascular Pharmacology 2009 51 1 1 7 2-s2.0-67349133681 10.1016/j.vph.2009.02.002
13. Mamehara A., Sugimoto T., Sugiyama D., Morinobu S., Tsuji G., Kawano S., Morinobu A., Kumagai S., Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe Journal of Medical Sciences 2010 56 3 E98 E107 2-s2.0-77958568501
14. Ribbens C., Martin y Porras M., Franchimont N., Kaiser M. J., Jaspar J. M., Damas P., Houssiau F. A., Malaise M. G., Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Annals of the Rheumatic Diseases 2002 61 2 161 166 2-s2.0-0036153347 10.1136/gut.0610161. (Pubitemid 34098433)
15. Young-Min S., Cawston T., Marshall N., Coady D., Christgau S., Saxne T., Robins S., Griffiths I., Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis and Rheumatism 2007 56 10 3236 3247 2-s2.0-35348910957 10.1002/art.22923 (Pubitemid 47585418)
16. Mattey D. L., Nixon N. B., Dawes P. T., Ollier W. E. R., Hajeer A. H., Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arhtritis. Genes and Immunity 2004 5 2 147 149 2-s2.0-3242808141 10.1038/sj.gene.6364050 (Pubitemid 38967645)
17. Tchetverikov I., Lard L. R., DeGroot J., Verzijl N., TeKoppele J. M., Breedveld F. C., Huizinga T. W. J., Hanemaaijer R., Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Annals of the Rheumatic Diseases 2003 62 11 1094 1099 2-s2.0-0142249505 10.1136/ard.62.11.1094 (Pubitemid 37323575)
18. Green M. J., Gough A. K. S., Devlin J., Smith J., Astin P., Taylor D., Emery P., Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003 42 1 83 88 2-s2.0-0037242710 10.1093/rheumatology/keg037 (Pubitemid 36131572)
19. Posthumus M. D., Limburg P. C., Westra J., Van Leeuwen M. A., Van Rijswijk M. H., Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. Journal of Rheumatology 2002 29 5 883 889 2-s2.0-0036257081 (Pubitemid 34493487)
20. Ribbens C., Andre B., Jaspar J. M., Kaye O., Kaiser M. J., De Groote D., Malaise M. G., Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. Journal of Rheumatology 2000 27 4 888 893 2-s2.0-0034120698 (Pubitemid 30389742)
21. Posthumus M. D., Limburg P. C., Westra J., Van Leeuwen M. A., Van Rijswijk M. H., Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. Journal of Rheumatology 2000 27 12 2761 2768 2-s2.0-0033663810
22. Yamanaka H., Matsuda Y., Tanaka M., Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2000 43 4 852 858
23. Cheung N. T., Dawes P. T., Poulton K. V., Ollier W. E. R., Taylor D. J., Mattey D. L., High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. Journal of Rheumatology 2000 27 4 882 887 2-s2.0-0034123127 (Pubitemid 30389741)
24. Ichikawa Y., Yamada C., Horiki T., Hoshina Y., Uchiyama M., Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clinical and Experimental Rheumatology 1998 16 5 533 540 2-s2.0-0031656122 (Pubitemid 28439434)
25. So A., Chamot A. M., Péclat V., Gerster J. C., Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology 1999 38 5 407 410 2-s2.0-0032725003 10.1093/rheumatology/38.5.407 (Pubitemid 29507123)
26. Kokubun M., Imafuku Y., Okada M., Ohguchi Y., Ashikawa T., Yamada T., Yoshida H., Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clinica Chimica Acta 2005 360 1-2 97 102 2-s2.0-24044445220 10.1016/j.cccn.2005.04.006 (Pubitemid 41225398)
27. Meyer P. W. A., Hodkinson B., Ally M., Anderson R., Musenge E., Wadee A. A., Fickl H., Tikly M., Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators of Inflammation 2010 2010 10 2-s2.0-79955032428 10.1155/2010/158514 158514
28. Hodkinson B., Musenge E., Ally M., Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis. Clinical Rheumatology 2012 31 4 613 619
29. Meyer P. W., Hodkinson B., Ally M., HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients. Arthritis Research and Therapy 2011 13 5, article R160
30. Tezenas Du Montcel S., Michou L., Petit-Teixeira E., Osorio J., Lemaire I., Lasbleiz S., Pierlot C., Quillet P., Bardin T., Prum B., Cornelis F., Clerget-Darpoux F., New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility. Arthritis and Rheumatism 2005 52 4 1063 1068 2-s2.0-20244385126 10.1002/art.20989 (Pubitemid 40530112)
31. Gourraud P. A., Boyer J. F., Barnetche T., Abbal M., Cambon-Thomsen A., Cantagrel A., Constantin A., A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for rheumatoid arthritis structural severity. Arthritis and Rheumatism 2006 54 2 593 599 2-s2.0-32444434913 10.1002/art.21630 (Pubitemid 43228636)
32. Tadbir A. A., Purshahidi S., Ebrahimi H., Khademi B., Malekzadeh M., Mardani M., Taghva M., Sardari Y., Serum level of MMP-3 in patients with oral squamous cell carcinoma-lack of association with clinico-pathological features. Asian Pacific Journal of Cancer Prevention 2012 13 9 4545 4548 10.7314/APJCP.2012.13.9.4545
33. Jordan J. M., Cartilage oligomeric matrix protein as a marker of osteoarthritis. Journal of Rheumatology 2004 31 70 45 49 2-s2.0-1942486454 (Pubitemid 38524568)
34. Migita K., Kawabe Y., Tominaga M., Origuchi T., Aoyagi T., Eguchi K., Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Laboratory Investigation 1998 78 5 535 539 2-s2.0-0031805385 (Pubitemid 28246977)
35. Nagasawa H., Kameda H., Amano K., Takeuchi T., Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis. APLAR Journal of Rheumatology 2007 10 4 295 299 2-s2.0-36749051813 10.1111/j.1479-8077.2007.00309.x (Pubitemid 350214821)
36. Visvanathan S., Marini J. C., Smolen J. S., Clair S., Pritchard C., Shergy W., Pendley C., Baker D., Bala M., Gathany T., Han J., Wagner C., Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. Journal of Rheumatology 2007 34 7 1465 1474 2-s2.0-34447515614 (Pubitemid 47067980)
37. Fujikawa K., Kawakami A., Tamai M., Uetani M., Takao S., Arima K., Iwamoto N., Aramaki T., Kawashiri S., Ichinose K., Kamachi M., Nakamura H., Origuchi T., Ida H., Aoyagi K., Eguchi K., High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. Journal of Rheumatology 2009 36 6 1126 1129 2-s2.0-67149101462 10.3899/jrheum.080926
38. Morozzi G., Fabbroni M., Bellisai F., Cucini S., Simpatico A., Galeazzi M., Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clinical Rheumatology 2007 26 8 1335 1338 2-s2.0-34447130787 10.1007/s10067-006-0520-y (Pubitemid 47034192)
39. Morozzi G., Fabbroni M., Bellisai F., Pucci G., Galeazzi M., Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments. Annals of the New York Academy of Sciences 2007 1108 398 407 2-s2.0-34948911750 10.1196/annals.1422.041 (Pubitemid 47528752)
40. Posey K. L., Hecht J. T., The role of cartilage oligomeric matrix protein (COMP) in skeletal disease. Current Drug Targets 2008 9 10 869 877 2-s2.0-65849384082